Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Peking University
Information provided by (Responsible Party):
Tao OUYANG, Peking University Identifier:
First received: April 28, 2012
Last updated: June 16, 2014
Last verified: June 2014

This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.

Condition Intervention Phase
Metastatic Breast Cancer
Drug: Capecitabine
Drug: Etoposide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

Resource links provided by NLM:

Further study details as provided by Peking University:

Primary Outcome Measures:
  • Clinical benefit rate [ Time Frame: 24 weeks after the treatment ] [ Designated as safety issue: No ]
    Clinical benefit is defined as CR, PR, SD≥24 weeks.

Estimated Enrollment: 54
Study Start Date: January 2013
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental Drug: Capecitabine
Drug:capecitabine 700mg/m2, twice daily on days 1-14.
Drug: Etoposide
Etoposide 30mg/m2, once daily on days 1-7.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • female patients between 18 and 65 years old
  • patients with metastatic breast cancer previousely treated with A/T
  • able and willing to give consent to participate in the study

Exclusion Criteria:

  • pregnant or lactating females
  • other tumor history
  • instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection
  • concurrent disease or condition that would make the patient inappropriate for study participation
  • resist to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01589159

Contact: Yan Wei, Doctor 0086-10-88196012

China, Beijing
Peking University Cancer Hospital & Institute Recruiting
Beijing, Beijing, China, 100142
Contact: Yan Wei, Doctor    0086-10-88196012   
Sponsors and Collaborators
Study Chair: Yan Wei, Doctor Peking University Cancer Hospital & Institute
  More Information

No publications provided

Responsible Party: Tao OUYANG, Chairman of Breast Center, Peking University Identifier: NCT01589159     History of Changes
Other Study ID Numbers: BCP09
Study First Received: April 28, 2012
Last Updated: June 16, 2014
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Etoposide phosphate
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on February 27, 2015